Han Cui-Cui, Yue Li-Ling, Yang Ying, Jian Bai-Yu, Ma Li-Wei, Liu Ji-Cheng
Institute of Medicine, Qiqihar Medical University, Qiqihar, Heilongjiang 161042, P.R. China.
Oncol Lett. 2016 Mar;11(3):1762-1768. doi: 10.3892/ol.2016.4117. Epub 2016 Jan 15.
TOX3 is a newly identified gene that has been observed to correlate with breast cancer by genome-wide association studies (GWAS) in recent years. In addition, it has been noted that single-nucleotide polymorphisms (SNPs) in the TOX3 gene have a strong correlation with estrogen receptor (ER)-positive tumors. However, the role of TOX3 in breast carcinoma development is still unclear. There are limited studies on the subject of TOX3 mRNA expression in breast tumors and little information on the variation of TOX3 protein expression in relation to the clinical pathological features in breast cancer and healthy tissues. In this study, we characterize the protein expression of TOX3 in breast tumors with respect to various clinical and pathological characteristics and explore the correlation between TOX3 protein expression and ER-positive tumors. A breast cancer tissue microarray containing 267 human breast tumors and 25 healthy controls, breast cancer cell lines (ZR-75-1, MDA-MB-231, MCF-7 and Bcap-37) with positive or negative ER expression, tumor tissues and matched controls were used to analyze the protein expression levels of TOX3 by immunohistochemistry, western blot analysis and quantitative polymerase chain reaction. Among the 267 breast tumor specimens, ER expression was detected in 66 tumor tissues. The expression levels of TOX3 increased in breast carcinoma tissue compared with controls, and were higher in advanced carcinoma (T3 and T4), lymph node metastases tissues (N2) and stage III tissues. Furthermore, TOX3 protein expression was more intense in ER-positive tumors, but did not demonstrate a statistical significance. However, it was significantly increased in ER-positive breast cancer cell lines (ZR-75-1, MCF-7 and Bcap-37) compared with the MDA-MB-231 cell line, which had ER-negative expression. Our findings provide support to the hypothesis that TOX3 has a strong correlation with the development of breast cancer. The current study is likely to assist in investigating the mechanisms involved in breast cancer development.
TOX3是一个近年来通过全基因组关联研究(GWAS)发现与乳腺癌相关的新基因。此外,有研究指出TOX3基因中的单核苷酸多态性(SNP)与雌激素受体(ER)阳性肿瘤密切相关。然而,TOX3在乳腺癌发生发展中的作用仍不明确。目前关于TOX3 mRNA在乳腺肿瘤中的表达研究有限,且关于TOX3蛋白表达变化与乳腺癌及健康组织临床病理特征之间关系的信息也很少。在本研究中,我们针对各种临床和病理特征,对TOX3在乳腺肿瘤中的蛋白表达进行了表征,并探讨了TOX3蛋白表达与ER阳性肿瘤之间的相关性。我们使用了包含267例人类乳腺肿瘤和25例健康对照的乳腺癌组织芯片、具有ER阳性或阴性表达的乳腺癌细胞系(ZR-75-1、MDA-MB-231、MCF-7和Bcap-37)、肿瘤组织及配对对照,通过免疫组织化学、蛋白质印迹分析和定量聚合酶链反应来分析TOX3的蛋白表达水平。在这267例乳腺肿瘤标本中,66例肿瘤组织检测到ER表达。与对照相比,TOX3在乳腺癌组织中的表达水平升高,在晚期癌(T3和T4)、淋巴结转移组织(N2)和III期组织中更高。此外,TOX3蛋白在ER阳性肿瘤中的表达更强,但未显示出统计学意义。然而,与ER阴性表达的MDA-MB-231细胞系相比,TOX3蛋白在ER阳性乳腺癌细胞系(ZR-75-1、MCF-7和Bcap-37)中显著升高。我们的研究结果支持了TOX3与乳腺癌发生密切相关的假说。本研究可能有助于探究乳腺癌发生发展的相关机制。